Oppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) is one of the top 10 defensive stocks to consider in a volatile market.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ayrshire Capital Management John Nevin Jr. | 39,526 | $5,375,920 | -11% | 2.58% |
| 2. | Zevenbergen Capital Investments Nancy Zevenbergen | 21,009 | $2,857,434 | +1% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing | |
| $72.32 | 100 | $7,231.50 | 6,400 | 2019-01-31 | Filing | |
| $72.31 | 100 | $7,230.50 | 6,300 | 2019-01-31 | Filing | |
| $72.33 | 1,800 | $130,194.00 | 6,200 | 2019-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing | |
| $138.17 | 949 | $131,123.33 | 74,381 | 2025-03-03 | Filing | |
| $138.17 | 562 | $77,651.54 | 31,970 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,614,322 | $219,563,936 | 0.25% | |
| 2. | 1,388,100 | $188,698,314 | 0.88% | |
| 3. | 1,338,060 | $179,888,785 | 0.3% | |
| 4. | 490,915 | $66,769,408 | 0.73% | |
| 5. | 425,277 | $57,841,925 | 0.45% |
News See All
10 Best Defensive Stocks to Buy in a Volatile Market
Investor positioning in defensive stock is at its lowest level it has ever been since 2000.
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc.
10 High Profit Margin Stocks to Buy Now
On June 24, Chris Hyzy, Merrill and BofA Private Bank CIO, joined 'Closing Bell' on CNBC to discuss his bullish outlook on the stock market.
Abbott Laboratories (ABT) Surged Ahead of the Market in 2025 with Steady Earnings Momentum
In the first quarter of 2025, the company delivered strong earnings and outperformed a group of medical device peers, despite challenging conditions driven by tariffs.
15 Best Dividend Stocks of 2025
After underperforming the market in seven of the past eight years, the Morningstar Dividend Leaders Index has made a strong comeback in 2025.
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio.
Early Retirement Portfolio: Top 15 Stock Picks
The Fed predicted two-quarter-percentage-point decreases this year at its most recent statement in March, which is consistent with current market pricing.
Leerink Partners Begins Coverage on ABT
The company is a Dividend King with 53 consecutive years of dividend growth. Its five-year average annual dividend growth rate sits at nearly 11%.
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management
Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc.
Billionaire Hedge Funds
